Cancer, Non-small cell lung carcinoma
GNLXGenelux CorporationCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Olvi-Vec (Olvimulogene nanivacirepvec) in Cancer, Non-small cell lung carcinoma. The expected timing is based on the latest available company guidance and may change.
VIRO-25 trial. 10/22/24- First patient dosed in Ph2. 8/7/25- Interim readout in H2 2025. 11/05/25:- Systemic NSCLC Ph2 VIRO-25 dose-escalation ongoing; additional interim data planned for Q4 2025 with further lung program updates expected throughout 2026. 01/05/26:- Interim Phase 2 VIRO-25 systemic NSCLC data show 60% disease control; further updated lung data expected throughout 2026. 03/19/26:- VIRO-25 interim NSCLC data show 60% disease control; tumor size changes to -22.7%; more updates during 2026. 05/07/26:- January 2026 VIRO-25 NSCLC data reiterated; 60% disease control; further dose-finding updates expected through 2026. 08/13/26:- Phase 2 VIRO-25 dose-finding updates are expected in 2026.
Verification
Confirm timing and program details against the company announcement or filing.